The development of therapies for TBI has mirrored the course followed by new treatments for stroke -- a sequence of frustrating failures. Some companies are now working closely with the US Army in developing the next generation of therapeutic candidates, including Neuren Pharmaceuticals, Banyan Biomarkers, and Maas Biolabs. Neuren's promising neuroprotectant will enter two Army-sponsored clinical trials during 2007. Other companies with active TBI programs include Xytis Pharmaceuticals, KeyNeurotek, RemeGenix, and Transition Therapeutics. There are neuroprotectant programs currently aimed at other indications which could also have applicability in TBI, such as those being developed by Allon Therapeutics (TSX: NPC) and Sygnis.

NeuroInvestment's April issue also includes commentary on the ACP-103 results that have been so high-profile for Acadia Pharmaceuticals (NASDAQ: ACAD), as well as a spotlight review of Acadia as a whole; the positive Phase IIa data for Alexza (NASDAQ: ALXA); the IPO filing by Jazz Pharmaceuticals; and the ongoing saga of Cephalon's complicated relationship with the FDA and FTC.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1500, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three month trial subscription is US$450.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and is now introducing an annual compendium of all neuro-oriented R&D programs organized by disorder, CNS 2007. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.